AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34758759 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual daily activities)
Number of subjects: 51
Study 34758759 — intervention group
Group type: EXPERIMENTAL
Intervention: Both experimental groups (EG1 and EG2)
Number of subjects: 51
Study 35761363 — intervention group
Group type: EXPERIMENTAL
Intervention: PEP4PA intervention (multilevel, peer-led program including self-monitoring, health coaching, group walks, social support, community advocacy)
Number of subjects: 476
Study 35761363 — intervention group
Group type: EXPERIMENTAL
Intervention: PEP4PA intervention
Number of subjects: 476
Study 35761363 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual programming)
Number of subjects: 476
Study 35761363 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 476
Study 36099141 — intervention group
Group type: EXPERIMENTAL
Intervention: ANS 0 (39 patients)
Number of subjects: 123
Study 36099141 — intervention group
Group type: EXPERIMENTAL
Intervention: ANS 1 (51 patients)
Number of subjects: 123
Study 36099141 — intervention group
Group type: EXPERIMENTAL
Intervention: ANS 2 (33 patients)
Number of subjects: 123
Study 36099141 — intervention group
Group type: COMPARATOR
Intervention: ANS 0
Number of subjects: 123
Study 36099141 — intervention group
Group type: COMPARATOR
Intervention: ANS 1
Number of subjects: 123
Study 36099141 — intervention group
Group type: EXPERIMENTAL
Intervention: ANS 2
Number of subjects: 123
Study 32569429 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 0.1% capsaicin cream
Number of subjects: 30
Study 32569429 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 30
Study 36394475 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular low-dose sustained-release morphine (0/8/16/24 mg every 24 hours)
Number of subjects: 20
Study 34187862 — intervention group
Group type: COMPARATOR
Intervention: Home medication
Number of subjects: 462
Study 34187862 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonhome medication
Number of subjects: 462
Study 32420825 — intervention group
Group type: EXPERIMENTAL
Intervention: Group social work intervention (8 sessions)
Number of subjects: 58
Study 32420825 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 58
Study 35658908 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep Learning Image Reconstruction (DLIR) - High intensity (H)
Number of subjects: 25
Study 35658908 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep Learning Image Reconstruction (DLIR) - Medium intensity (M)
Number of subjects: 25
Study 35658908 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep Learning Image Reconstruction (DLIR) - Low intensity (L)
Number of subjects: 25
Study 35658908 — intervention group
Group type: COMPARATOR
Intervention: Adaptive Statistical Iterative Reconstruction V (ASiR-V) - 50%
Number of subjects: 25
Study 35658908 — intervention group
Group type: COMPARATOR
Intervention: Adaptive Statistical Iterative Reconstruction V (ASiR-V) - 30%
Number of subjects: 25
Study 35658908 — intervention group
Group type: COMPARATOR
Intervention: Filtered Back Projection (FBP)
Number of subjects: 25
Study 33630199 — intervention group
Group type: EXPERIMENTAL
Intervention: Stronger Together intervention (a three‐session dyadic intervention involving HIV testing and adherence counseling)
Number of subjects: 318
Study 33630199 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SOC) control arm
Number of subjects: 318
Study 32885419 — intervention group
Group type: EXPERIMENTAL
Intervention: Okara soup (4.1 g fiber/meal)
Number of subjects: 52
Study 32885419 — intervention group
Group type: COMPARATOR
Intervention: Placebo (soymilk, 0.1 g fiber/meal)
Number of subjects: 52
Study 35610666 — intervention group
Group type: EXPERIMENTAL
Intervention: GeneXpert® point‐of‐care diagnostic testing for Neisseria gonorrhoeae, Chlamydia trachomatis, and Trichomonas vaginalis, with same‐day treatment for detected infection(s). Arm 1 will additionally receive a test‐of‐cure 3 weeks post‐treatment, while Arm 2 will receive a repeat test at 30‐34 weeks' gestation.
Number of subjects: 2500
Study 35610666 — intervention group
Group type: COMPARATOR
Intervention: Syndromic management (standard‐of‐care)
Number of subjects: 2500
Study 33750369 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking initiation
Number of subjects: 588190
Study 33750369 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy alcohol consumption
Number of subjects: 588190
Study 33750369 — intervention group
Group type: COMPARATOR
Intervention: Age at initiation of regular smoking, cigarettes per day, and smoking cessation
Number of subjects: 588190
Study 32604436 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational and cognitive-behavioral counseling (8 sessions, 1.5 hours each, 2 sessions per week)
Number of subjects: 70
Study 32604436 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational and cognitive-behavioral counseling
Number of subjects: 70
Study 36099496 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreatic stent placement (PS)
Number of subjects: 321
Study 36099496 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal diclofenac (NSAID) 50 mg
Number of subjects: 321
Study 36099496 — intervention group
Group type: EXPERIMENTAL
Intervention: Both pancreatic stent placement and rectal NSAIDs (PS + NSAID)
Number of subjects: 321
Study 36099496 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 321
Study 33476774 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced usual care
Number of subjects: 0
Study 33476774 — intervention group
Group type: COMPARATOR
Intervention: Novel model of collaborative care
Number of subjects: 0
Study 32320533 — intervention group
Group type: EXPERIMENTAL
Intervention: RAINBOW intervention
Number of subjects: 409
Study 32320533 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 409
Study 36194613 — intervention group
Group type: EXPERIMENTAL
Intervention: Parallel cable configuration
Number of subjects: 12
Study 36194613 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi cable configuration
Number of subjects: 12
Study 36194613 — intervention group
Group type: COMPARATOR
Intervention: Overall preference
Number of subjects: 12
Study 33629812 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 mg day-1 xanthohumol for eight weeks
Number of subjects: 30
Study 33629812 — intervention group
Group type: COMPARATOR
Intervention: Placebo for eight weeks
Number of subjects: 30
Study 32862830 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 dose of RBX2660 via enema
Number of subjects: 0
Study 32862830 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 doses of RBX2660 via enema
Number of subjects: 0
Study 32862830 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32875946 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium hydroxide 5% solution (KOH)
Number of subjects: 18
Study 32875946 — intervention group
Group type: COMPARATOR
Intervention: 5-fluorouracil cream (5-FU)
Number of subjects: 18
Study 34836002 — intervention group
Group type: EXPERIMENTAL
Intervention: MIPS before training and CHO plus protein after training (PRE-MIPS)
Number of subjects: 30
Study 34836002 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO plus protein plus MIPS after training (POST-MIPS)
Number of subjects: 30
Study 34836002 — intervention group
Group type: COMPARATOR
Intervention: CHO plus protein after training (CG)
Number of subjects: 30
Study 35859087 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal contraception
Number of subjects: 400
Study 35859087 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study 33474700 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual Pressure Release (MPR)
Number of subjects: 20
Study 33474700 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical Neuromodulation (ENM)
Number of subjects: 20
Study 32054509 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-week oral Phe administration
Number of subjects: 30
Study 32054509 — intervention group
Group type: COMPARATOR
Intervention: 4-week placebo administration
Number of subjects: 30
Study 35239109 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinic BP measurements
Number of subjects: 510
Study 35239109 — intervention group
Group type: EXPERIMENTAL
Intervention: Home BP measurements
Number of subjects: 510
Study 35239109 — intervention group
Group type: EXPERIMENTAL
Intervention: Kiosk BP measurements
Number of subjects: 510
Study 33070469 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (10 mg/mL)
Number of subjects: 40
Study 33070469 — intervention group
Group type: COMPARATOR
Intervention: Placebo (20% intralipid)
Number of subjects: 40
Study 36235623 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-Glycerylphosphorylcholine (A-GPC) 1000 mg
Number of subjects: 12
Study 36235623 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 34526004 — intervention group
Group type: EXPERIMENTAL
Intervention: SP with VRNET
Number of subjects: 95
Study 34526004 — intervention group
Group type: COMPARATOR
Intervention: SP
Number of subjects: 95
Study 32530769 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin plus FU (60 mg/m2 on day 1 and 1,000 mg/m2 on days 1-4 every 21 days for 24 weeks)
Number of subjects: 91
Study 32530769 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin plus paclitaxel (AUC 5 on day 1 and 80 mg/m2 on days 1, 8, and 15 every 28 days for 24 weeks)
Number of subjects: 91
Study 32530769 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin plus FU
Number of subjects: 91
Study 32530769 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin plus paclitaxel
Number of subjects: 91
Study 35459000 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibrotactile sensory augmentation (SA)
Number of subjects: 16
Study 35459000 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 16
Study 34529887 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal preemptive analgesia (flurbiprofen axetil and oxycodone before skin incision combined with bilateral transverse abdominis plane block)
Number of subjects: 108
Study 34529887 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal preemptive analgesia
Number of subjects: 108
Study 34529887 — intervention group
Group type: COMPARATOR
Intervention: Control group (sufentanil and flurbiprofen axetil combined with bilateral TAPB in PACU)
Number of subjects: 108
Study 33894218 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-minute walk test (6MWT)
Number of subjects: 283
Study 33894218 — intervention group
Group type: EXPERIMENTAL
Intervention: self-selected speed (SSS) of gait
Number of subjects: 283
Study 33894218 — intervention group
Group type: EXPERIMENTAL
Intervention: Activities-specific Balance Confidence (ABC) scale
Number of subjects: 283
Study 33894218 — intervention group
Group type: EXPERIMENTAL
Intervention: Montreal Cognitive Assessment (MoCA)
Number of subjects: 283
Study 33894218 — intervention group
Group type: EXPERIMENTAL
Intervention: Area Deprivation Index (ADI)
Number of subjects: 283
Study 33894218 — intervention group
Group type: EXPERIMENTAL
Intervention: Charlson Comorbidity Index (CCI)
Number of subjects: 283
Study 33894218 — intervention group
Group type: EXPERIMENTAL
Intervention: steps per day (SPD)
Number of subjects: 283
Study 32558314 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial peptide KSL‐W formulated as an antiplaque chewing gum (APCG), 30 mg, administered three times per day for four days
Number of subjects: 26
Study 32558314 — intervention group
Group type: COMPARATOR
Intervention: Placebo gum
Number of subjects: 26
Study 35279155 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg
Number of subjects: 100
Study 35279155 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 34663123 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness training
Number of subjects: 54
Study 34663123 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducation
Number of subjects: 54
Study 34663123 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based delivery
Number of subjects: 54
Study 34663123 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote delivery
Number of subjects: 54
Study 34663123 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall program rating
Number of subjects: 54
Study 35526272 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose adalimumab regimen
Number of subjects: 0
Study 35526272 — intervention group
Group type: COMPARATOR
Intervention: Fixed dosing regimen
Number of subjects: 0
Study 35526272 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab exposure
Number of subjects: 0
Study 33004464 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin (10 and 25 mg)
Number of subjects: 7020
Study 33004464 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7020
Study 36435427 — intervention group
Group type: EXPERIMENTAL
Intervention: AI-optimized weekly interventions (combination of expert-led group, expert-led call, paraprofessional-led call, and automated message)
Number of subjects: 336
Study 36435427 — intervention group
Group type: COMPARATOR
Intervention: Gold standard condition (12 months of weekly BWL groups)
Number of subjects: 336
Study 34401332 — intervention group
Group type: EXPERIMENTAL
Intervention: puboprostatic ligament-sparing RARP (Group B)
Number of subjects: 92
Study 34401332 — intervention group
Group type: COMPARATOR
Intervention: standard RARP (Group A)
Number of subjects: 92
Study 34544626 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminders+LIA
Number of subjects: 460
Study 34544626 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined+LIA
Number of subjects: 460
Study 34544626 — intervention group
Group type: EXPERIMENTAL
Intervention: Vouchers
Number of subjects: 460
Study 33141417 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi plus normal care
Number of subjects: 67
Study 33141417 — intervention group
Group type: COMPARATOR
Intervention: Normal care
Number of subjects: 67
Study 34643713 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy dietary guidelines (HDG)
Number of subjects: 294
Study 34643713 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MED)
Number of subjects: 294
Study 34643713 — intervention group
Group type: EXPERIMENTAL
Intervention: Green-MED diet
Number of subjects: 294
Study 34643713 — intervention group
Group type: EXPERIMENTAL
Intervention: Men (sex-stratified analysis)
Number of subjects: 294
Study 33935074 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture (EA)
Number of subjects: 120
Study 33935074 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture (SA)
Number of subjects: 120
Study 33155305 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-week multicomponent program (group exercise, nutritional supplementation, management of depression, deprescribing, home hazard reduction)
Number of subjects: 383
Study 33155305 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 383
Study 35879748 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Recovery After Surgery (ERAS) protocol
Number of subjects: 85
Study 35879748 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 85
Study 33588293 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone laparoscopy simulator (SimuSurg)
Number of subjects: 30
Study 33588293 — intervention group
Group type: COMPARATOR
Intervention: Control group (no laparoscopic activity)
Number of subjects: 30
Study 32811637 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose of nine sessions of MET/CBT
Number of subjects: 87
Study 32811637 — intervention group
Group type: COMPARATOR
Intervention: PRN condition with smaller initial dose of treatment
Number of subjects: 87
Study 32811637 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (MET/CBT and PRN)
Number of subjects: 87
Study 33884468 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal myocardial perfusion scintigraphy (MPS)
Number of subjects: 400
Study 33884468 — intervention group
Group type: COMPARATOR
Intervention: Normal myocardial perfusion scintigraphy (MPS)
Number of subjects: 400
Study 33884468 — intervention group
Group type: COMPARATOR
Intervention: Completely normal MPS (SSS and SDS = 0)
Number of subjects: 400
Study 33884468 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal MPS with revascularization
Number of subjects: 400
Study 33543228 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAP laser combined with periodontal regeneration surgery
Number of subjects: 48
Study 33543228 — intervention group
Group type: COMPARATOR
Intervention: Conventional periodontal regeneration surgery alone
Number of subjects: 48
Study 34714961 — intervention group
Group type: EXPERIMENTAL
Intervention: Microneedling with a dermapen
Number of subjects: 62
Study 34714961 — intervention group
Group type: COMPARATOR
Intervention: Point-by-point technique injection
Number of subjects: 62
Study 34001032 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive strategy (n=1681)
Number of subjects: 3339
Study 34001032 — intervention group
Group type: COMPARATOR
Intervention: Conservative strategy (n=1658)
Number of subjects: 3339
Study 34001032 — intervention group
Group type: EXPERIMENTAL
Intervention: Paired catheterization data (n=259)
Number of subjects: 3339
Study 32969391 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate intranasal spray
Number of subjects: 126
Study 32969391 — intervention group
Group type: COMPARATOR
Intervention: Oral montelukast
Number of subjects: 126
Study 34628065 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg subcutaneously every 2 weeks for 24 weeks
Number of subjects: 724
Study 34628065 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 724
Study 36116287 — intervention group
Group type: EXPERIMENTAL
Intervention: BIVA guided ultrafiltration (UF) adjustment
Number of subjects: 65
Study 36116287 — intervention group
Group type: COMPARATOR
Intervention: Conventional clinical parameters for UF adjustment
Number of subjects: 65
Study 34805810 — intervention group
Group type: EXPERIMENTAL
Intervention: PB-201 50+50 mg
Number of subjects: 16
Study 34805810 — intervention group
Group type: EXPERIMENTAL
Intervention: PB-201 100+50 mg
Number of subjects: 16
Study 34805810 — intervention group
Group type: EXPERIMENTAL
Intervention: PB-201 100+100 mg
Number of subjects: 16
Study 34805810 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 33013035 — intervention group
Group type: EXPERIMENTAL
Intervention: Erector spinae plane (ESP) block with 0.2% ropivacaine (0.2 ml/kg on either side)
Number of subjects: 60
Study 33013035 — intervention group
Group type: COMPARATOR
Intervention: Transversus abdominis plane (TAP) block with 0.2% ropivacaine (0.2 ml/kg on either side)
Number of subjects: 60
Study 33013035 — intervention group
Group type: EXPERIMENTAL
Intervention: Erector spinae plane (ESP) block
Number of subjects: 60
Study 33013035 — intervention group
Group type: COMPARATOR
Intervention: Transversus abdominis plane (TAP) block
Number of subjects: 60
Study 32943158 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter Aortic Valve Replacement (TAVR)
Number of subjects: 5190
Study 32516497 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-use microneedle device only
Number of subjects: 29
Study 32516497 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of home-use microneedle device and 5% minoxidil solution
Number of subjects: 29
Study 32516497 — intervention group
Group type: COMPARATOR
Intervention: 5% minoxidil topical solution only
Number of subjects: 29
Study 32169887 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher CML-AGE intake
Number of subjects: 1592
Study 34861168 — intervention group
Group type: EXPERIMENTAL
Intervention: ianalumab 5 mg
Number of subjects: 190
Study 34861168 — intervention group
Group type: EXPERIMENTAL
Intervention: ianalumab 50 mg
Number of subjects: 190
Study 34861168 — intervention group
Group type: EXPERIMENTAL
Intervention: ianalumab 300 mg
Number of subjects: 190
Study 34861168 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 190
Study 35623816 — intervention group
Group type: EXPERIMENTAL
Intervention: Stevia (15.3 mg)
Number of subjects: 33
Study 35623816 — intervention group
Group type: EXPERIMENTAL
Intervention: d-tagatose (5000 mg)
Number of subjects: 33
Study 35623816 — intervention group
Group type: COMPARATOR
Intervention: Control (60 mL water)
Number of subjects: 33
Study 33141487 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 9
Study 33141487 — intervention group
Group type: COMPARATOR
Intervention: Control (historical cohort)
Number of subjects: 9
Study 33610836 — intervention group
Group type: EXPERIMENTAL
Intervention: ranibizumab (0.5 mg/50 μl)
Number of subjects: 267
Study 33610836 — intervention group
Group type: EXPERIMENTAL
Intervention: aflibercept (2.0 mg/50 μl)
Number of subjects: 267
Study 33610836 — intervention group
Group type: EXPERIMENTAL
Intervention: bevacizumab (1.25 mg/50 μl)
Number of subjects: 267
Study 33610836 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 267
Study 33677048 — intervention group
Group type: EXPERIMENTAL
Intervention: Involved-field irradiation with definitive chemoradiation therapy (61.2 Gy in 34 fractions using intensity modulated radiation therapy)
Number of subjects: 436
Study 33677048 — intervention group
Group type: EXPERIMENTAL
Intervention: Involved-field irradiation with definitive chemoradiation therapy
Number of subjects: 436
Study 33216008 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based alcohol intervention
Number of subjects: 306
Study 33143451 — intervention group
Group type: EXPERIMENTAL
Intervention: Galcanezumab 120 mg
Number of subjects: 0
Study 33143451 — intervention group
Group type: EXPERIMENTAL
Intervention: Galcanezumab 240 mg
Number of subjects: 0
Study 33143451 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35195337 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher strength of uterine contractions
Number of subjects: 0
Study 34018426 — intervention group
Group type: EXPERIMENTAL
Intervention: Very young candidates (< 35 years old)
Number of subjects: 93
Study 34018426 — intervention group
Group type: EXPERIMENTAL
Intervention: Male candidates
Number of subjects: 93
Study 34018426 — intervention group
Group type: EXPERIMENTAL
Intervention: Female candidates
Number of subjects: 93
Study 34018426 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived attractiveness and warmth
Number of subjects: 93